Abstract:ABSTRACT Staphylococcus aureus is an opportunistic pathogen causing osteomyelitis through hematogenous seeding or contamination of implants and open wounds following orthopedic surgeries. The severity of S. aureus -mediated osteomyelitis is enhanced in obesity-related type 2 diabetes (obesity/T2D) due to chronic inflammation impairing both adaptive and innate immunity. Obesity-induced inflammation is linked to gut dysbiosis, with modification of the gut microbiota by high-fiber diets leading to a reduction in the symptoms and complications of obesity/T2D. However, our understanding of the mechanisms by which modifications of the gut microbiota alter host infection responses is limited. To address this gap, we monitored tibial S. aureus infections in obese/T2D mice treated with the inulin-like fructan fiber, oligofructose. Treatment with oligofructose significantly decreased S. aureus colonization and lowered proinflammatory signaling post-infection in obese/T2D mice, as observed by decreased circulating inflammatory cytokines (TNF-α) and chemokines (IP-10, KC, MIG, MCP-1, and RANTES), indicating partial reduction in inflammation. Oligofructose markedly shifted diversity in the gut microbiota of obese/T2D mice mice, with notable increases in the anti-inflammatory bacterium, Bifidobacterium pseudolongum . Analysis of the cecum and plasma metabolome suggested polyamine production was increased, specifically spermine and spermidine. Oral administration of these polyamines to obese/T2D mice resulted in reduced infection severity similar to oligofructose supplementation, suggesting polyamines can mediate the beneficial effects of fiber on osteomyelitis severity. These results demonstrate the contribution of gut microbiota metabolites to the control of bacterial infections distal to the gut and polyamines as an adjunct therapeutic for osteomyelitis in obesity/T2D. Importance Individuals with obesity-related type 2 diabetes (obesity/T2D) are at a five times increased risk for invasive Staphylococcus aureus osteomyelitis (bone infection) following orthopedic surgeries. With increasing antibiotic resistance and limited discoveries of novel antibiotics, it is imperative we explore other avenues for therapeutics. In this study, we demonstrated that the dietary fiber oligofructose markedly reduced osteomyelitis severity and hyperinflammation following acute implant-associated osteomyelitis in obese/T2D mice. Reduced infection severity is associated with changes in gut microbiota composition and metabolism as indicated by increased production of natural polyamines in the gut and circulating plasma. This work identifies a novel role for the gut microbiome in mediating control of bacterial infections and polyamines as beneficial metabolites involved in improving the obesity/T2D host response to osteomyelitis. Understanding the impact of polyamines on host immunity and mechanisms behind decreasing susceptibility to severe implant-associated osteomyelitis is crucial to improving treatment strategies for this patient population.

Modulation of Gut Microbiota Metabolism in Obesity-Related Type 2 Diabetes Reduces Osteomyelitis Severity

Impact of altering gut microbiota metabolism on osteomyelitis severity in obesity-related type 2 diabetes

Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity

The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus

The role of Gut Microbiota in the development of obesity and Diabetes

Modulation of Gut Microbiota in the Management of Metabolic Disorders: The Prospects and Challenges

Gut microbiota and therapy for obesity and type 2 diabetes

Recent insights of obesity-induced gut and adipose tissue dysbiosis in type 2 diabetes

Insights Into the Role of the Microbiome in Obesity and Type 2 Diabetes

Microbial-Based Bioactive Compounds to Alleviate Inflammation in Obesity

Importance of gut microbiota in obesity

Modulation of bone remodeling by the gut microbiota: a new therapy for osteoporosis

Type 2 diabetes mellitus has a positive role in osteomyelitis: A Mendelian randomization analysis

Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet–Induced Obesity and Diabetes in Mice

Gut microbiota and obesity-associated osteoarthritis

Modulation of gut microbiota by antibiotics improves insulin signalling in high-fat fed mice

Microbiota, inflammation and obesity

Modulation of Gut Microbiota in Pathological States

Gut Microbiome Modulation Based on Probiotic Application for Anti-Obesity: A Review on Efficacy and Validation

Beyond Diet and Exercise: The Impact of Gut Microbiota on Control of Obesity

Type 2 diabetes mediates the causal relationship between obesity and osteomyelitis: A Mendelian randomization study